Literature DB >> 18438957

Assessing the impact of ICH E9.

David Brown1, Simon Day, Rob Hemmings, David Wright.   

Abstract

The ICH harmonized tripartite guideline 'Statistical Principles for Clinical Trials', more commonly referred to as ICH E9, was adopted by the regulatory bodies of the European Union, Japan and the USA in 1998. This document united related guidance documents on statistical methodology from each of the three ICH regions, and meant that for the first time clear consistent guidance on statistical principles was available to those conducting and reviewing clinical trials. At the 10th anniversary of the guideline's adoption, this paper discusses the influence of ICH E9 by presenting a perspective on how approaches to some aspects of clinical trial design, conduct and analysis have changed in that time in the context of regulatory submissions in the European Union. Copyright 2008 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Year:  2008        PMID: 18438957     DOI: 10.1002/pst.337

Source DB:  PubMed          Journal:  Pharm Stat        ISSN: 1539-1604            Impact factor:   1.894


  2 in total

1.  Statistical analysis of arthroplasty data. I. Introduction and background.

Authors:  Jonas Ranstam; Johan Kärrholm; Pekka Pulkkinen; Keijo Mäkelä; Birgitte Espehaug; Alma Becic Pedersen; Frank Mehnert; Ove Furnes
Journal:  Acta Orthop       Date:  2011-06       Impact factor: 3.717

2.  Regulatory scientific advice on non-inferiority drug trials.

Authors:  Grace Wangge; Michelle Putzeist; Mirjam J Knol; Olaf H Klungel; Christine C Gispen-De Wied; Antonius de Boer; Arno W Hoes; Hubert G Leufkens; Aukje K Mantel-Teeuwisse
Journal:  PLoS One       Date:  2013-09-05       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.